Childhood Asthma, Forty Pack-Years, and a Reversible Third of His Airflow
A patient with real COPD and real asthma both present in the same lungs, whose eosinophilia and reversibility argue for treating the asthma component directly rather than defaulting to whichever label came first.
Gerald N. still keeps a service bay two mornings a week at the auto shop he sold to his nephew five years ago, mostly to stay useful and partly because he says a quiet garage bothers him more than a noisy one. He smoked close to a pack a day for most of four decades before quitting three years ago, a history that shows up plainly on his spirometry. What complicates the picture is a second history layered on top of it: asthma as a child that mostly went quiet through his thirties, forties, and fifties, and has, in his own description, “come back with interest” over the past two years — wheezing episodes distinct from his baseline breathlessness, worse around cold air and his shop’s brake-dust exposure both.
His spirometry does not resolve cleanly into either diagnosis alone. Post-bronchodilator FEV1/FVC of 0.62 confirms real, fixed airflow obstruction, the kind his smoking history would predict on its own. But his bronchodilator response — an 18% and 250 mL improvement in FEV1 after albuterol — is well past what fixed COPD-only obstruction typically shows, and his blood eosinophil count of 410/µL adds a third data point pointing the same direction as the reversibility and the childhood history: a real asthmatic component sitting inside airways that also have real, smoking-driven structural damage. He is currently on LAMA/LABA dual bronchodilator therapy alone, the standard COPD-first approach, and has had one moderate exacerbation on it despite reasonable symptom control day to day. That combination is what makes the label he ends up with consequential rather than semantic. GOLD 2026 does not treat an inhaled corticosteroid as one option among several once concomitant asthma is established — it says such patients should be managed as asthma patients, with ICS use mandatory; and its separate eosinophil route to the same place, escalation at 100 cells/µL in an exacerbating patient on dual bronchodilators, he clears four times over. Two independent paths through the same guideline arrive at a steroid for him, which is a firmer position than either the reversibility or the eosinophil count would carry on its own.
Two diagnoses in one set of lungs, deciding which one leads
Three separate signals are pointing the same direction here, not one ambiguous finding I am stretching to interpret. His bronchodilator response of 18% and 250 mL is well past what fixed COPD alone typically shows, his blood eosinophil count is real and elevated, and his childhood asthma has genuinely recurred rather than being an old chart note. When concomitant asthma is present like this, current guidance treats an inhaled corticosteroid as close to mandatory, not the optional add-on it can be for COPD by itself. I would add ICS now.
I am not disputing the reversibility or the eosinophil count. What I want said plainly is that he also has a real, forty-pack-year smoking history and confirmed fixed obstruction underneath whatever reversible component is layered on top — and inhaled corticosteroids carry a genuine pneumonia-risk signal in exactly this kind of smoking-driven, structurally damaged lung. I do not want an asthma-overlap label applied so readily that it skips past the ordinary caution we would apply to any COPD patient with his history before adding a steroid.
I agree with adding ICS today — the convergence of findings is real. What I would flag now, before it becomes relevant, is what happens if triple therapy is not enough. His eosinophilia would in principle make him eligible for an asthma-style biologic, but the evidence for how those drugs actually perform in overlap patients specifically, rather than in patients with pure asthma, is genuinely thinner. Sun and colleagues’ 2026 retrospective cohort comparing omalizumab response in ACO against non-ACO asthma found real, blunted efficacy in the overlap group, and concluded that the Th2-high inflammatory pattern predicts response better than the ACO label itself does. I should say the evidence is not one-directional — the PROSPERO post-hoc analysis found ACO and non-ACO patients did comparably on omalizumab however ACO was defined, and it is the larger dataset of the two. Which is rather the point: two studies asking the same question have come out differently. What I do not want is anyone assuming a biologic will work here exactly the way it does in a textbook asthma patient, if we get to that point.
Agreed: add inhaled corticosteroid to his existing dual bronchodilator regimen, treating the convergent reversibility, eosinophilia, and asthma-history findings as real evidence for a genuine asthmatic component rather than incidental texture on a COPD diagnosis.
Not fully agreed and explicitly carried forward rather than resolved: how much weight a future biologic decision should give to his smoking-driven COPD history versus his eosinophilia, if triple therapy does not adequately control him. The allergist flagged the overlap-specific evidence gap without recommending for or against a biologic today, since the question is not yet live.